Biotech Values

[DewDiligence]

ACIP’s RSV votes today (all unanimous):

• RSV vaccination recommended unconditionally for adults age 75+.

• RSV vaccination recommended for adults age 60-74 who have one of the following conditions: lung disease, cardiovascular disease, moderate or severe immunocompromise, diabetes with end organ damage, severe obesity, neurological or neuromuscular conditions, advanced chronic kidney disease, liver disorder, or blood disorders.

• No recommendation at this time that adults age 50-59 should get GSK’s Arexvy, despite the fact that the FDA recently approved Arexvy for age 50-59 (#msg-174567339).

ACIP did not recommended any change to the existing CDC guidance that individuals should seek a “shared” decision with their healthcare provider on whether to get vaccinated for RSV. Hence, adults age 60-74 who do not fit into the third bullet item above remain in “shared decision” limbo, at least for now.

Also, ACIP did not make any recommendation on whether—or when—people should receive a second RSV vaccination.

https://www.statnews.com/2024/06/26/cdc-rsv-acip-hearing/